Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

BACKGROUND: Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. CASE PRESENTATION: We report three consecutive Caucasian patients, two female...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikanjam, Mina, Mullen, Jaren, Yacoub, Carol, Daniels, Gregory A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429475/
https://www.ncbi.nlm.nih.gov/pubmed/36045435
http://dx.doi.org/10.1186/s13256-022-03536-y
_version_ 1784779456068452352
author Nikanjam, Mina
Mullen, Jaren
Yacoub, Carol
Daniels, Gregory A.
author_facet Nikanjam, Mina
Mullen, Jaren
Yacoub, Carol
Daniels, Gregory A.
author_sort Nikanjam, Mina
collection PubMed
description BACKGROUND: Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. CASE PRESENTATION: We report three consecutive Caucasian patients, two female (60 and 55 years old) and one male (56 years old), refractory to anti-programmed cell death-1 therapy who were treated with concurrent nivolumab and standard-dosing bolus high-dose interleukin-2. We did not see any unexpected toxicities with overlapping treatments as compared with either high-dose interleukin-2 or nivolumab alone. CONCLUSIONS: The tolerance and disease control observed among the three patients in this limited series support formal exploration of this combination.
format Online
Article
Text
id pubmed-9429475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94294752022-09-01 Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series Nikanjam, Mina Mullen, Jaren Yacoub, Carol Daniels, Gregory A. J Med Case Rep Case Report BACKGROUND: Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. CASE PRESENTATION: We report three consecutive Caucasian patients, two female (60 and 55 years old) and one male (56 years old), refractory to anti-programmed cell death-1 therapy who were treated with concurrent nivolumab and standard-dosing bolus high-dose interleukin-2. We did not see any unexpected toxicities with overlapping treatments as compared with either high-dose interleukin-2 or nivolumab alone. CONCLUSIONS: The tolerance and disease control observed among the three patients in this limited series support formal exploration of this combination. BioMed Central 2022-08-31 /pmc/articles/PMC9429475/ /pubmed/36045435 http://dx.doi.org/10.1186/s13256-022-03536-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Nikanjam, Mina
Mullen, Jaren
Yacoub, Carol
Daniels, Gregory A.
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title_full Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title_fullStr Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title_full_unstemmed Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title_short Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
title_sort combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429475/
https://www.ncbi.nlm.nih.gov/pubmed/36045435
http://dx.doi.org/10.1186/s13256-022-03536-y
work_keys_str_mv AT nikanjammina combinationhighdoseinterleukin2andnivolumabforprogrammedcelldeath1refractorymetastaticmelanomaacaseseries
AT mullenjaren combinationhighdoseinterleukin2andnivolumabforprogrammedcelldeath1refractorymetastaticmelanomaacaseseries
AT yacoubcarol combinationhighdoseinterleukin2andnivolumabforprogrammedcelldeath1refractorymetastaticmelanomaacaseseries
AT danielsgregorya combinationhighdoseinterleukin2andnivolumabforprogrammedcelldeath1refractorymetastaticmelanomaacaseseries

Ejemplares similares